Data on GlycoMimetics' Drug Candidate's Potential to Treat Lung Infections Caused by Pseudomonas Aeruginosa to Be Presented at North American Cystic Fibrosis Conference
The poster will highlight proof-of-principle research studies on the efficacy of GMI-1051 to treat lung infections caused by P. aeruginosa, a bacteria that often demonstrates antibiotic resistance. The studies highlighted in the poster evaluated the ability of GMI-1051 to improve the efficacy of infection-fighting treatments by targeting bacterial virulence factors that are known to play important roles in the proliferation and survival of the bacteria. In animal models of acute and chronic lung infection, use of GMI-1051 enhanced innate immunity in the host, facilitated clearance of the bacteria and improved overall survival in combination therapy as compared to antibiotics alone.
"Early research findings such as these substantiate our work on this potential therapy for Pseudomonas, a difficult to treat infection and a major concern for the cystic fibrosis community," said
The poster (#354) entitled, "Glycomimetic Antagonists of the Virulence Factors of P. aeruginosa (PA-IL and PA-IIL) Protect Innate Immune Cells and Increase the Efficacy of Antibiotic Treatment in a Chronic Lung Infection Model," will be featured in Poster Session I on
The meeting abstract is available at the NACFC website: https://www.nacfconference.org/about.html
About GMI-1051
About
Cautionary Note on Forward-Looking Statements
The statements in this press release that are not historical facts constitute "forward-looking statements" that involve risks and uncertainties and are made pursuant to the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by their use of terms and phrases such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, or the negative of such terms, and include, but are not limited to,
CONTACT:Source:Brian Hahn Email: bhahn@glycomimetics.com Phone: 240-243-1207
News Provided by Acquire Media